Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.
Cell. 2021 Jan 21;184(2):384-403.e21. doi: 10.1016/j.cell.2020.12.031. Epub 2021 Jan 14.
Cell. 2021.
PMID: 33450205
Free PMC article.